{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T07:10:38Z","timestamp":1697958638801},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T00:00:00Z","timestamp":1205971200000},"content-version":"vor","delay-in-days":8206,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[1985,10]]},"abstract":"<jats:p><jats:bold>Abstract. <\/jats:bold> In order to evaluate the interaction between the opiate\u2010like peptidergic pathways and the dopaminergic system in modulating prolactin (PRL) secretion, ten normal volunteers were studied according to a double\u2010blind, cross\u2010over, randomized experimental design. A group of five subjects was given a fixed dose of sulpiride (a selective antidopaminergic agent, 25 mg i.v.) plus either placebo or three different doses of naloxone (a selective opioid antagonist, 02,0\u20134,0\u20108 mg i.v.) while a second group of five subjects received the same drugs in a \u2018reverse\u2019 protocol, i.e. a fixed dose of naloxone (0\u20134 mg i.v.) plus either placebo or increasing doses of sulpiride (25, 50, 100 mg i.v.). In both groups, the drugs were injected simultaneously and blood samples for PRL determination were taken at various intervals during the 15 min preceding drug injections and then over the following 4 h. Naloxone (0\u20134 mg i.v.) per se did not induce any modification of plasma PRL levels, but reduced to a significant extent sulpiride\u2010induced hyperprolactinaemia (<jats:italic>P<\/jats:italic>&lt;0\u00b702). However, a higher dose of naloxone (0\u20138 mg i.v.) did not cause significant changes in sulpiride\u2010stimulated PRL levels. Increasing dosages of sulpiride (up to 100 mg i.v.) reversed the blunted response of PRL after sulpiride, 25 mg, in presence of naloxone. Our data show that naloxone, at a dose of 0\u20134 mg i.v. inactive per se on basal PRL levels, is able to blunt significantly sulpiride\u2010induced hyperprolactinaemia. This suggests that, in man, opioid peptides are able to influence PRL release after antidopaminergic stimuli.<\/jats:p>","DOI":"10.1111\/j.1365-2362.1985.tb00183.x","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T13:03:42Z","timestamp":1206018222000},"page":"272-275","source":"Crossref","is-referenced-by-count":1,"title":["Naloxone inhibits sulpiride\u2010induced hyperprolactinaemia in man"],"prefix":"10.1111","volume":"15","author":[{"given":"G. P.","family":"BERNINI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"PEDRINELLI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"SALVETTI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"FRANCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"LUISI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.6.3006"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90001-8"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(79)90142-2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-50-3-516"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-50-2-251"},{"key":"e_1_2_1_7_2","first-page":"150","article-title":"Opiate receptors and anterior pituitary hormone secretion in man. Effect of naloxone infusion","volume":"97","author":"Delitala G","year":"1981","journal-title":"Acta Endocrinol (Kbh)"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-1-181"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(76)90056-3"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.0720273"},{"key":"e_1_2_1_11_2","first-page":"420","article-title":"The human pharmacology and abuse potential of n\u2010allynoroxy morphone (naloxone)","volume":"157","author":"Jasinski DR","year":"1967","journal-title":"J. Pharmacol Exp Ther"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)91879-5"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92100-1"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00543803"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90411-9"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90534-4"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-106-1-76"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-106-5-1469"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/264567a0"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/oxfordjournals.bmb.a071789","article-title":"Distribution and physiological significance of opioid receptors in the brain","volume":"39","author":"Fatweh S","year":"1983","journal-title":"Br Med Bull"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(79)90403-X"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(77)90415-5"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(78)90360-0"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/280595a0"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-110-3-812"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.1985.tb00183.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.1985.tb00183.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:26:32Z","timestamp":1697865992000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.1985.tb00183.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,10]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1985,10]]}},"alternative-id":["10.1111\/j.1365-2362.1985.tb00183.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.1985.tb00183.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,10]]}}}